Stability Criterion for the Assembly of Core–Shell Lipid–Polymer–Nucleic Acid Nanoparticles
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Hybrid core–shell lipid–polycation–nucleic acid nanoparticles (LPNPs) provide unique delivery strategies for nonviral gene therapeutics. Since LPNPs consist of multiple components, involving different pairwise interactions between them, they are challenging to characterize and understand. Here, we propose a method based on fluorescence cross-correlation spectroscopy to elucidate the association between the three LPNP components. Through this lens, we demonstrate that cationic lipid shells (liposomes) do not displace polycations or DNA from the polycation–DNA cores (polyplexes). Hence, polyplexes and liposomes must be oppositely charged to associate into LPNPs. Furthermore, we identify the liposome:polyplex number ratio ( ρ N ), which was hitherto an intangible quantity, as the primary parameter predicting stable LPNPs. We establish that ρ N ≥ 1 ensures that every polyplex is enveloped by a liposome, thus avoiding coexisting oppositely charged species prone to aggregation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · RNA and protein synthesis mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
International Iberian Nanotechnology Laboratory, Braga, 4715-330, Portugal
Funding
Fundaci?n Ram?n Areces · European Regional Development Fund · Funda??o para a Ci?ncia e a Tecnologia
References (35)
Show source-provided references
1. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
2. 10.1126/science.abm082910.1126/science.abm0829 ↗
3. 10.1038/nature1830010.1038/nature18300 ↗
4. 10.1038/nature2300310.1038/nature23003 ↗
5. 10.1056/NEJMoa210745410.1056/NEJMoa2107454 ↗
6. 10.1126/science.281.5373.7810.1126/science.281.5373.78 ↗
7. 10.1073/pnas.172054211510.1073/pnas.1720542115 ↗
8. 10.1021/acsnano.8b0151610.1021/acsnano.8b01516 ↗
9. 10.1038/s41565-021-01030-y10.1038/s41565-021-01030-y ↗
10. 10.3390/pharmaceutics1309136510.3390/pharmaceutics13091365 ↗
11. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
12. 10.1021/jm200237p10.1021/jm200237p ↗
13. 10.1016/j.jconrel.2014.04.02310.1016/j.jconrel.2014.04.023 ↗
14. 10.1016/B978-0-12-800148-6.00005-510.1016/B978-0-12-800148-6.00005-5 ↗
15. 10.1002/ange.20160845010.1002/ange.201608450 ↗
16. 10.1016/j.biomaterials.2017.02.01910.1016/j.biomaterials.2017.02.019 ↗
17. 10.1038/nm.435610.1038/nm.4356 ↗
18. 10.1038/s41551-018-0284-010.1038/s41551-018-0284-0 ↗
19. 10.1002/adhm.20190170510.1002/adhm.201901705 ↗
20. 10.1021/cr500679310.1021/cr5006793 ↗
21. 10.1021/acsnano.8b0096610.1021/acsnano.8b00966 ↗
22. 10.1016/j.cis.2013.08.00810.1016/j.cis.2013.08.008 ↗
23. 10.3390/cells909203410.3390/cells9092034 ↗
24. 10.1038/nprot.2007.41010.1038/nprot.2007.410 ↗
25. 10.1073/pnas.200844711710.1073/pnas.2008447117 ↗
26. 10.1002/jbio.20200020010.1002/jbio.202000200 ↗
27. 10.1038/nnano.2012.21210.1038/nnano.2012.212 ↗
28. 10.1002/adma.20170675910.1002/adma.201706759 ↗
29. 10.1021/jp404812a10.1021/jp404812a ↗
30. 10.1021/nl303581q10.1021/nl303581q ↗
31. 10.1039/C5CC06767G10.1039/C5CC06767G ↗
32. 10.1021/acs.chemmater.6b0003010.1021/acs.chemmater.6b00030 ↗
33. 10.1073/pnas.223568810010.1073/pnas.2235688100 ↗
34. 10.1002/cphc.20110080110.1002/cphc.201100801 ↗
35. 10.1002/cphc.20180057610.1002/cphc.201800576 ↗